InnoCare Presents Data on Orelabrutinib at European Hematology Association Congress

InnoCare presented data on their drug pipeline at the European Hematology Association (EHA) 2023 Hybrid Congress. The company's orelabrutinib, an inhibitor of Bruton’s Tyrosine Kinase, was evaluated in a study to treat Primary Immune Thrombocytopenia. Results showed that both doses of orelabrutinib were safe for patients with ITP, and those who had previously responded to glucocorticoids or intr..